National Bank of Canada FI acquired a new stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 45,000 shares of the company's stock, valued at approximately $3,459,000. National Bank of Canada FI owned about 0.16% of GeneDx as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also made changes to their positions in WGS. Barclays PLC grew its holdings in GeneDx by 346.3% during the third quarter. Barclays PLC now owns 18,921 shares of the company's stock valued at $803,000 after purchasing an additional 14,681 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in GeneDx in the 3rd quarter valued at $325,000. Charles Schwab Investment Management Inc. raised its holdings in GeneDx by 304.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company's stock worth $6,240,000 after acquiring an additional 110,666 shares during the period. Franklin Resources Inc. acquired a new position in GeneDx during the 3rd quarter worth $301,000. Finally, Prudential Financial Inc. bought a new stake in GeneDx during the fourth quarter valued at about $7,938,000. 61.72% of the stock is owned by institutional investors.
GeneDx Stock Performance
GeneDx stock traded up $4.01 during trading hours on Friday, hitting $96.63. The stock had a trading volume of 856,334 shares, compared to its average volume of 672,104. The company has a 50-day moving average of $90.43 and a two-hundred day moving average of $78.11. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a fifty-two week low of $8.63 and a fifty-two week high of $115.60. The company has a market cap of $2.71 billion, a PE ratio of -49.30 and a beta of 1.93.
GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The business had revenue of $95.64 million during the quarter, compared to analyst estimates of $82.24 million. On average, equities research analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on WGS shares. The Goldman Sachs Group lifted their price objective on GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. TD Cowen lifted their price target on GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $72.33.
Check Out Our Latest Analysis on GeneDx
Insider Activity
In other news, CEO Katherine Stueland sold 1,657 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total value of $130,041.36. Following the completion of the transaction, the chief executive officer now directly owns 3,937 shares of the company's stock, valued at approximately $308,975.76. This represents a 29.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Kevin Feeley sold 402 shares of GeneDx stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $90.05, for a total value of $36,200.10. Following the completion of the transaction, the chief financial officer now directly owns 5,044 shares of the company's stock, valued at $454,212.20. This represents a 7.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 138,780 shares of company stock worth $12,907,437. 27.30% of the stock is currently owned by corporate insiders.
About GeneDx
(
Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Read More
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
